Research Studies
Sage-718 DIMENSION
Criteria
About this study
This phase 2 study seeks to evaluate the effect of the study drug SAGE-718 on the cognition of participants with premanifest or recent HD diagnosis. You can participate if you are between 25 to 65 years of age and have been diagnosed with early HD